HIV Clinical Trial
Official title:
A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection
Background:
- In most people who have human immunodeficiency virus (HIV), the immune system cannot
control or cure the infection. Antiretroviral therapy drugs can keep the amount of HIV virus
low for a long time. However, this treatment does not remove the virus from the body. In the
vast majority of patients antiretroviral therapy also will not protect the body from the
virus once treatment stops. Researchers want to see if therapeutic vaccination can help
people with HIV. Therapeutic vaccination means giving vaccines to treat an infection that
someone already has (HIV, in this case). It may help the body's immune system attack the
infection. This study will look at different measures of HIV infection after receiving either
therapeutic vaccination or a placebo.
Objectives:
- To see whether therapeutic vaccination is safe and can affect how the body responds to HIV
infection.
Eligibility:
- Individuals between 18 and 65 years of age who have HIV and are taking antiretroviral
therapy drugs.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected.
- During the screening visit and throughout the study until week 56, participants will
continue to take their HIV medications.
- Participants will be divided into two groups. One group will have the study vaccines.
The other will have a placebo.
- The first study vaccine or placebo will be given in weeks 4, 12, and 36. The second
study vaccine or the placebo will be given in weeks 24 and 48. Blood samples and other
tests will be given at each visit.
- After the study visit at week 56, participants will stop their HIV medications until
week 72. From weeks 58 through 72, they will come in every 2 weeks for study visits;
each visit will take about 1 hour to complete. These visits will look at the body s
response to the vaccines and their HIV viral load. After week 72, participants will
re-start their HIV medications.
- There will be follow-up study visits from weeks 76 to 96, with blood tests and other
studies.
The advent of combination antiretroviral therapy (cART) has dramatically improved the
clinical outcome in human immunodeficiency virus (HIV)-infected individuals through sustained
reduction in viral replication. However, it has become clear that cART alone cannot eradicate
HIV in infected individuals, likely in part due to the persistence of viral reservoirs in
peripheral blood and various tissue compartments. Consequently, a major thrust of HIV
research over the past several years has been to develop therapeutic strategies that can
eliminate persistent viral reservoirs and boost host immunity to control viral replication
upon discontinuation of cART. Therapeutic HIV vaccination is one approach that could
potentially achieve these goals through vaccine-induced improvement in HIV-specific immune
responses and/or by direct reactivation of HIV-specific CD4+ memory T cells that harbor
latent HIV. An effective therapeutic vaccine could augment immunologic control of HIV
infection and potentially obviate the need for chronic cART.
The current study is an exploratory randomized, 2-arm (1:1), double-blind, placebo-controlled
trial evaluating the safety and efficacy of an HIV-1 multiantigen plasmid DNA (HIV-MAG pDNA)
vaccine prime in combination with an interleukin-12 plasmid DNA (IL-12 pDNA) adjuvant
delivered by in vivo electroporation followed by a recombinant vesicular stomatitis virus
vector containing the HIV-1 gag gene (rVSV HIV gag) booster vaccine in subjects on cART who
started therapy during acute or early HIV infection.
Subjects will be randomized to receive placebo or the HIV-MAG pDNA (3000 g) vaccine prime and
IL-12 pDNA adjuvant (1000 g) at week 0, 4, 12, and 36, and the rVSV HIV gag booster vaccine
(1x107 plaque-forming units) at week 24 and 48. The HIV-MAG pDNA vaccine prime and IL-12 pDNA
adjuvant will be administered as 2 IM injections, 1 into each deltoid, with electroporation
using the Ichor TDS device, while the rVSV HIV gag booster vaccine will be administered as 2
conventional IM injections, 1 into each deltoid. After the week 56 visit, all subjects will
undergo an analytical treatment interruption to determine if the vaccination strategy results
in an improved immune control of viral replication, as evidenced by a blunted or absent
rebound in HIV plasma viremia. All subjects will be followed through week 96 for safety and
efficacy parameters.
The study population includes HIV-infected adults who began cART during acute or early
infection. Subjects must be receiving an effective cART regimen, with a CD4 cell count of
>450 cells/mm3 at screening, and they must have documented viral suppression below the limit
of detection for greater than1 year. The rationale for testing the study vaccine regimen in
this subject population is because these individuals may have a relatively preserved immune
function, which could be augmented by therapeutic vaccination.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |